Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-04

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19

NCT04329572

COVID-19

SUSPENDED EARLY_PHASE1

Asymptomatic COVID-19 Trial

NCT04374552

SARS-CoV-2 Infection

WITHDRAWN PHASE2

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)

NCT04322123

Coronavirus Infections

COMPLETED PHASE3

Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients

NCT04371406

Covid-19

WITHDRAWN PHASE3

Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

NCT04322396

Virus Diseases Infection Viral Corona Virus Infection

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase III trial will utilize four treatment strategies in non-critically ill hospitalized participants (not requiring mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin. Investigators are primarily interested in the time to recovery. In addition to study medications there will be daily symptom surveys for 14 days, then weekly thereafter for 4 weeks resulting in a total duration of follow up of 42 days. During hospitalization, daily symptom surveys will be completed in conjunction with the study coordinators. On discharge participants will have the option to complete electronic symptom surveys or complete symptom surveys via telephone with study coordinator. In the event that the participant opts for electronic symptom surveys on discharge participants will in addition receive a follow up call from a study coordination every 7 days during the initial 14 day period. In addition, failure to submit a symptom survey will prompt a study follow up call. Data from standard of care SOC will be collected from medical records.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

Antimalarial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine Sulfate

anti-rheumatic drug (DMARD)

Intervention Type DRUG

Azithromycin

Antibiotic

Intervention Type DRUG

Chloroquine Sulfate

Antimalarial

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HYDROXYCHLOROQUINE Plaquenil COMMON BRAND(S): Zithromax GENERIC NAME(S): Azithromycin Aralen GENERIC NAME(S): Chloroquine Phosphate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hospitalization for management of SARS CoV-2 infection
* Positive SARS CoV-2 test
* Age \>=18 years
* Provision of informed consent
* Electrocardiogram (ECG) ≤48 hours prior to enrollment
* Complete blood count, glucose-6 phosphate-dehydrogenase (G6PD), comprehensive metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.
* If participating in sexual activity that could lead to pregnancy, individuals of reproductive potential who can become pregnant must agree to use contraception throughout the study. At least one of the following must be used throughout the study:

* Condom (male or female) with or without spermicide
* Diaphragm or cervical cap with spermicide
* Intrauterine device (IUD)
* Hormone-based contraceptive

Exclusion Criteria

* Contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin
* Current use hydroxychloroquine, chloroquine or azithromycin
* Concurrent use of another investigational agent
* Invasive mechanical ventilation
* Participants who have any severe and/or uncontrolled medical conditions such as:

* unstable angina pectoris,
* symptomatic congestive heart failure,
* myocardial infarction,
* cardiac arrhythmias or know prolonged QTc \>470 males, \>480 female on ECG
* pulmonary insufficiency,
* epilepsy (interaction with chloroquine),
* Prior retinal eye disease
* Concurrent malignancy requiring chemotherapy
* Known Chronic Kidney disease, eGFR\<10 or dialysis
* G-6-PD deficiency, if unknown requires G6PD testing prior to enrollment

* Known Porphyria
* Known myasthenia gravis
* Currently pregnant or planning on getting pregnant while on study
* Breast feeding
* AST/ALT \>five times the upper limit of normal ULN\*
* Bilirubin \>five times the ULN\*
* Magnesium \<1.4 mEq/L\*
* Calcium \<8.4mg/dL \>10.6mg/dL\*
* Potassium \<3.3 \>5.5 mEg/L\*

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No